Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) EPS (Basic) (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed EPS (Basic) for 7 consecutive years, with -$0.99 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 30.28% to -$0.99 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.77 through Dec 2025, down 31.36% year-over-year, with the annual reading at -$3.78 for FY2025, 31.25% down from the prior year.
  • EPS (Basic) hit -$0.99 in Q4 2025 for BridgeBio Pharma, down from -$0.95 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.07 in Q2 2022 to a low of -$1.42 in Q4 2024.
  • Historically, EPS (Basic) has averaged -$0.89 across 5 years, with a median of -$0.95 in 2025.
  • Biggest five-year swings in EPS (Basic): surged 89.39% in 2022 and later crashed 1300.0% in 2023.
  • Year by year, EPS (Basic) stood at -$1.02 in 2021, then grew by 9.8% to -$0.92 in 2022, then decreased by 4.35% to -$0.96 in 2023, then crashed by 47.92% to -$1.42 in 2024, then surged by 30.28% to -$0.99 in 2025.
  • Business Quant data shows EPS (Basic) for BBIO at -$0.99 in Q4 2025, -$0.95 in Q3 2025, and -$0.95 in Q2 2025.